Peptide Guide + Calculator
DSIP Reconstitution Calculator & Guide
Delta Sleep-Inducing Peptide / Emideltide
DSIP, also called delta sleep-inducing peptide or emideltide, is an experimental nine-amino-acid peptide studied mainly in small human sleep trials from the 1980s and early 1990s. The evidence for insomnia is mixed and preliminary, its proposed role as a natural human sleep factor remains unresolved, and there is no FDA-approved DSIP drug. This page explains the current evidence, FDA compounding review, safety limitations, and educational reconstitution math.
Evidence Snapshot
DSIP research at a glance
Standardized regulatory and evidence context so research compounds, investigational drugs, and approved medications are not treated as if they have the same level of human evidence.
Regulatory status
Not FDA-approvedDevelopment / evidence stage
Early human studies (historical)
Historical clinical development
Human evidence level
Human pharmacology / early clinicalPrimary mechanism
Neuropeptide historically associated with sleep regulation; mechanism and physiological role remain uncertain.
WADA context
Non-approved substance — S0 may applyHuman intervention evidence
Small controlled human insomnia and withdrawal-related studies were performed, but results were inconsistent and did not establish a major therapeutic benefit.
Human biology evidence
Older human sleep research exists, but the peptide's physiological role and mechanism remain incompletely defined.
Key takeaway
DSIP is not purely preclinical, but its human evidence is old, small, inconsistent, and far from an established sleep treatment.
Evidence labels describe the research base and regulatory context; they are not treatment, dosing, or use recommendations. Review dates describe the last BACToBasics source check for this evidence summary. Anti-doping rules can change and should be verified with the applicable authority.
DSIP Reconstitution Calculator
Enter the vial amount, liquid volume, and amount you want to calculate. BACToBasics will automatically calculate concentration, liquid volume, and U-100 syringe-unit equivalents.
Loading calculator...
Calculator values are educational math inputs only. They are not recommended preparation amounts, doses, or use protocols.
DSIP Reconstitution Math
Reconstitution math starts with the amount contained in the vial and the liquid volume used in the calculation. Dividing the vial amount by the liquid volume gives the resulting concentration.
Example vial amount
5 mg
| Liquid Volume | Calculation | Concentration |
|---|---|---|
| 1 mL | 5 mg ÷ 1 mL | 5 mg/mL |
| 2 mL | 5 mg ÷ 2 mL | 2.5 mg/mL |
| 3 mL | 5 mg ÷ 3 mL | 1.6667 mg/mL |
This table demonstrates concentration math only. The liquid volumes shown are examples for comparison and are not preparation recommendations.
More Reconstitution Tools
Need to compare different liquid volumes or convert between mg, mcg, mL, and U-100 units? Use the dedicated BACToBasics calculator tools.
What is DSIP?
DSIP stands for delta sleep-inducing peptide. The international nonproprietary name emideltide is also used. The peptide is reported as the nine-amino-acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was originally described in sleep-related research decades ago and later studied in small human experiments involving insomnia, sleep physiology, pain, and withdrawal symptoms.
Is DSIP really a natural sleep hormone?
That description is not firmly established. DSIP was originally reported in biological material and became known for sleep-related effects, but later reviews have emphasized that its endogenous physiology remains uncertain. A 2006 review described the hypothesis that DSIP itself is a physiological sleep factor as poorly documented and unresolved, with uncertainty about its natural occurrence, biological activity, and mechanism.
What does human sleep research show?
Most human research on DSIP is old, small, and based on intravenous administration. Several early studies reported changes in sleep duration, sleep latency, or sleep efficiency, but later controlled studies produced weaker or inconsistent findings. The overall evidence does not resemble the modern development program normally required to establish an insomnia medication's efficacy and safety.
The 1992 double-blind insomnia study
A double-blind study in 16 people with chronic insomnia compared intravenous DSIP with placebo over several laboratory nights. Some objective measures, including sleep efficiency and sleep latency, favored DSIP. However, the investigators concluded that the effects were weak, some could have reflected an incidental change in the placebo group, and short-term DSIP treatment was unlikely to provide major therapeutic benefit for chronic insomnia.
Other controlled insomnia findings
A 1987 double-blind crossover study in six patients with severe chronic insomnia found some increases in total sleep time and stage-2 sleep, but the authors concluded that the overall sleep improvement was of little clinical significance. FDA's 2026 review similarly concluded that available intravenous insomnia studies were inconclusive and at best preliminary.
Does DSIP increase deep or delta sleep?
The name can make this sound established, but the evidence is more complicated. Early animal and human research associated DSIP with sleep-related EEG effects, yet controlled human studies did not consistently show meaningful increases in slow-wave sleep. The biological mechanism responsible for any sleep effects remains uncertain.
DSIP and opioid or alcohol withdrawal
Small historical studies also investigated intravenous DSIP during alcohol or opioid withdrawal. Some reports described improvement in withdrawal symptoms, but the studies were limited by older methodology, small samples, incomplete follow-up, and lack of the controls expected in modern drug development. FDA's 2026 review did not identify evidence supporting the proposed subcutaneous route for opioid withdrawal.
DSIP for stress, pain, recovery, or longevity
DSIP is frequently marketed online for stress tolerance, recovery, pain, hormone regulation, and longevity. These broader claims are largely based on older animal studies, small exploratory human reports, or biological hypotheses. There is not strong modern clinical evidence establishing DSIP as a treatment for these purposes.
Is DSIP FDA-approved?
No FDA-approved drug contains emideltide or DSIP. In its 2026 Pharmacy Compounding Advisory Committee review, FDA evaluated emideltide free base and emideltide acetate for chronic insomnia, narcolepsy, and opioid withdrawal. FDA stated that neither substance is a component of an FDA-approved drug and that the evaluation criteria weighed against adding them to the section 503A Bulks List.
What did FDA conclude about subcutaneous DSIP?
FDA specifically noted that it found no effectiveness data for the nominated subcutaneous route for chronic insomnia, narcolepsy, or opioid withdrawal. The human studies FDA identified primarily involved intravenous administration, so results from those studies should not be assumed to establish the safety or effectiveness of subcutaneous products sold online.
What is known about DSIP safety?
Human safety data are limited and mostly come from small historical intravenous studies. FDA reported transient headache, nausea, vertigo, and cases of hypotension, including progressive hypotension after a subsequent intravenous injection in a withdrawal study. FDA also cited concerns involving peptide aggregation, impurities, active-ingredient characterization, and potential immunogenicity for compounded products.
DSIP and competitive sports
DSIP is not explicitly named in the 2026 WADA Prohibited List. However, WADA's S0 category prohibits pharmacological substances that are not addressed elsewhere in the List and have no current approval by a governmental regulatory health authority for human therapeutic use. Athletes subject to anti-doping rules should therefore verify DSIP's status with their governing body rather than assuming that an unnamed peptide is permitted.
Research products vs approved medicines
A vial marketed online as DSIP should not be treated as equivalent to an FDA-approved medicine. There is no FDA-approved DSIP product with an established clinical indication, standardized commercial formulation, validated dosing regimen, or approved labeling. Product identity, purity, concentration, sterility, and stability can also vary outside regulated pharmaceutical manufacturing.
DSIP reconstitution math
Reconstitution calculations depend only on the labeled vial amount and the liquid volume entered. As a math example, a 5mg vial combined with 2mL of liquid produces a concentration of 2.5mg per mL, or 2,500mcg per mL. BACToBasics uses examples like this to demonstrate concentration, liquid-volume, and U-100 syringe-unit calculations, not to recommend a DSIP preparation or dosing protocol.
Explore more about DSIP
11 linksComparisons, research records, development tracking, blends, and related guides are available here when you want to go deeper.
Explore more about DSIP
11 linksComparisons, research records, development tracking, blends, and related guides are available here when you want to go deeper.
Compare DSIP
Direct comparison pages are selected from the indexable BACToBasics comparison catalog and update automatically as that catalog grows.
Research, updates & development
Jump from the guide into the public update timeline, compound-specific research records, and clinical-development tracker without searching again.
DSIP research & development updates
Open the public timeline of sourced research records and material development changes tracked by BACToBasics.
Open →
ResearchDSIP research sources
Open 1 curated research record for DSIP.
Open →
DevelopmentDSIP clinical development
Early human studies (historical) · Historical clinical development. Small double-blind insomnia studies reported weak or inconsistent clinical effects.
Open →
Related peptide guides
Related guides are ranked from shared comparison pages, shared blend pages, and peptide category rather than a hand-maintained link list.
Epitalon guide & calculator
Longevity & Wellness · Synthetic Pineal Tetrapeptide
Open →
Peptide guideBremelanotide guide & calculator
Longevity & Wellness · PT-141 / Vyleesi
Open →
Peptide guideElamipretide guide & calculator
Longevity & Wellness · SS-31 / Forzinity
Open →
Peptide guideMOTS-C guide & calculator
Longevity & Wellness · Mitochondrial-Derived Peptide
Open →
Relevant glossary concepts
Definitions are matched against the guide's structured title, subtitle, description, and educational sections.
FDA-Approved
A status indicating that the FDA has approved a specific drug product for one or more labeled uses after reviewing the required evidence and manufacturing information.
Open →
GlossaryMilliliter (mL)
A metric unit of liquid volume equal to one-thousandth of a liter.
Open →
GlossaryConcentration
The amount of a substance contained in a given volume of liquid, such as mg/mL or mcg/mL.
Open →
DSIP FAQ
Tap a question to expand only the answer you want to read.
What does DSIP stand for?
DSIP stands for delta sleep-inducing peptide. The international nonproprietary name emideltide is also used for the peptide.
Is DSIP FDA-approved?
No. FDA's 2026 review states that emideltide free base and emideltide acetate are not components of an FDA-approved drug.
Does DSIP cure insomnia?
No reliable evidence establishes DSIP as a cure or approved treatment for insomnia. Small historical trials produced mixed results, and FDA characterized the available evidence as inconclusive and at best preliminary.
Does DSIP improve sleep quality?
Some small studies reported changes in sleep efficiency, latency, or total sleep time, while other controlled studies found little clinically meaningful benefit. The overall evidence is inconsistent.
Does DSIP increase deep sleep?
That has been proposed, but controlled human studies have not consistently demonstrated a clinically meaningful increase in slow-wave or deep sleep.
Is DSIP a naturally occurring human hormone?
Its status as a physiological endogenous human sleep factor remains unresolved. Scientific reviews have questioned whether the material historically measured as DSIP-like immunoreactivity represents DSIP itself or related molecules.
Are there modern clinical trials of DSIP?
The best-known human studies are small trials from the 1980s and early 1990s. The evidence base lacks the large modern randomized Phase 2 and Phase 3 programs normally used to establish an insomnia treatment.
Has DSIP been studied for opioid withdrawal?
Yes. Small historical intravenous studies explored DSIP for opioid and alcohol withdrawal, but the evidence is limited and does not establish a modern approved treatment.
What side effects have been reported with DSIP?
Historical intravenous studies reported effects including headache, nausea, vertigo, and hypotension in some participants. Long-term and subcutaneous safety remain inadequately characterized.
Has subcutaneous DSIP been proven effective?
No. FDA's 2026 review stated that it did not identify effectiveness data supporting the nominated subcutaneous route for chronic insomnia, narcolepsy, or opioid withdrawal.
Is DSIP prohibited by WADA?
DSIP is not explicitly named in the 2026 WADA list. WADA's S0 rule can nevertheless prohibit non-approved pharmacological substances that are not addressed elsewhere, so tested athletes should verify current status with an appropriate anti-doping authority.
What concentration results from 5mg of DSIP in 2mL?
Mathematically, 5mg divided by 2mL equals 2.5mg/mL, which is 2,500mcg/mL. This is a concentration example rather than a dosing recommendation.
What does the DSIP calculator calculate?
It converts a labeled vial amount and entered liquid volume into concentration, then calculates the liquid volume and U-100 syringe-unit equivalent for an entered amount. It does not determine an appropriate DSIP dose.
Sources & References
6 sourcesOpen the references when you want to inspect the research and regulatory sources behind this guide.
Sources & References
6 sourcesOpen the references when you want to inspect the research and regulatory sources behind this guide.
FDA's July 2026 review of emideltide free base and acetate, including chemistry, insomnia, narcolepsy, opioid-withdrawal evidence, safety, and proposed subcutaneous use.
FDA summary of potential immunogenicity, peptide-impurity, API-characterization, and route-specific safety concerns for emideltide.
1992 double-blind study in 16 chronic insomnia patients; authors concluded that short-term DSIP was unlikely to provide major therapeutic benefit.
1987 controlled sleep study reporting that observed sleep improvement was of little clinical significance.
2006 review discussing uncertainty around DSIP's endogenous physiology, identity, and proposed role as a sleep factor.
Current anti-doping list including S0, which addresses non-approved pharmacological substances not covered by later sections.
BACToBasics provides educational information and math tools only. This content is not medical advice, dosing advice, injection instruction, or a recommendation to use any peptide or medication.